Monster Lung Cavity in a Heart Transplant Recipient

Heart Surg Forum. 2018 Mar 5;21(2):E072-E074. doi: 10.1532/hsf.1922.

Abstract

Invasive mucormycosis infections occur in less than 1% of recipients of orthotopic heart transplants. Given the angioinvasive nature of these infections, the mortality rate is high. Little literature exists regarding the presentation and management of these infections. We present a case of a patient who developed an infection after orthotopic heart transplant, describe the successful multidisciplinary management surrounding his care, and review the available literature regarding mucormycosis infections in heart transplant recipients.

Keywords: antifungal therapy; heart transplantation; immunosuppression; mucormycosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / therapeutic use
  • Follow-Up Studies
  • Heart Failure / surgery*
  • Heart Transplantation / adverse effects*
  • Humans
  • Lung / diagnostic imaging*
  • Lung / surgery
  • Lung Diseases, Fungal / diagnosis
  • Lung Diseases, Fungal / etiology*
  • Lung Diseases, Fungal / therapy
  • Male
  • Mucormycosis / diagnosis
  • Mucormycosis / etiology*
  • Mucormycosis / therapy
  • Pneumonectomy / methods
  • Postoperative Complications*
  • Tomography, X-Ray Computed
  • Transplant Recipients*

Substances

  • Antifungal Agents